103286-53-9Relevant articles and documents
A Hexanuclear Cadmium Metal–Organic Framework Exhibiting Dual Mechanisms to Trigger a Fluorescence-Quenching Response toward Iron(III) Ions
Li, Long-Sheng,Wang, Xi,Jia, Yan-Yuan,Xu, Shi-Xian,Yu, Mei-Hui,Zhang, Ying-Hui
, p. 1068 - 1072 (2018)
A hexanuclear CdII metal–organic framework (1) based on 4-(1H-pyrazole-4-carboxamido)benzoic acid (H2L) and featuring a three-dimensional microporous framework was synthesized. Notably, 1 shows a unique fluorescence-quenching response toward Fe3+ ions with high selectivity and sensitivity (Stern–Volmer constant KSV = 2.07 × 104 m–1). The response is attributable to the coaction of absorption competition and energy-transfer (ET) mechanism. Furthermore, spectral analysis indicates that the energy-transfer mechanism makes the dominant contribution to the fluorescence quenching of 1.
Preparation method of key intermediate 2 for synthesizing baricitinib
-
Paragraph 0075; 0076; 0093; 0105, (2018/04/28)
The invention relates to a preparation method of a key intermediate 2 for synthesizing baricitinib. The preparation method comprises the following process steps: respectively synthesizing an intermediate A, an intermediate B, an intermediate D and the key intermediate 2. The preparation method has the advantages that commercially available raw materials, i.e. 1H-pyrazole-4-formic acid (SM1), ethylcyanoacetate (SM2), 2-bromo-1,1-diethoxyethane (SM3) and formamidine acetate ( SM4) are used as starting materials, and the key intermediate 2 is obtained after only four steps of chemical reactionsare carried out; the use of starting materials such as 4-chloropyrrolo[2,3-d]pyrimidine and pyrazol borate which are high in material cost is avoided, and the production cost of the key intermediate 2is lowered.
Therapeutic Compounds
-
Page/Page column 26, (2011/04/25)
Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3 and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.